Home > Riviste > The Journal of Cardiovascular Surgery > Fascicoli precedenti > The Journal of Cardiovascular Surgery 2020 August;61(4) > The Journal of Cardiovascular Surgery 2020 August;61(4):489-95

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE  CARDIAC SECTION 

The Journal of Cardiovascular Surgery 2020 August;61(4):489-95

DOI: 10.23736/S0021-9509.20.11083-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Transfemoral transcatheter aortic valve replacement without contrast medium using the Medtronic CoreValve system: a single center experience

Diego MAFFEO 1, Luca BETTARI 1, Azeem LATIB 2, 3, Cristian MAIANDI 1, Emmanuel VILLA 4, Antonio MESSINA 4, Matteo SACCOCCI 4 , Andrea ARNERI 5, Claudio CUCCIA 1, Giovanni TROISE 4

1 Department of Cardiology, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy; 2 EMO-GVM Centro Cuore Columbus, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy; 3 Department of Cardiology, Montefiore Medical Center, New York, NY, USA; 4 Department of Cardiothoracic Surgery, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy; 5 Medtronic Italia, Coronary and Structural Heart, Milan, Italy



BACKGROUND: Transcatheter aortic valve replacement (TAVR) in patients with chronic kidney disease (CKD) is challenging due to the high risk of contrast-induced nephropathy (CIN) and acute kidney injury (AKI). AKI dramatically reduces the clinical benefit of TAVR and is one of the strongest predictors of 30-day mortality as well as long-term adverse outcomes after TAVR. The aim of this study was to evaluate a protocol specifically designed to reduce the incidence of contrast-induced nephropathy (CIN) in advanced CKD patients screened for and undergoing TAVR.
METHODS: Twelve consecutive patients with severe aortic valve stenosis suffering from at least stage 4 CKD underwent both screening with pre-procedural computed tomography scan (CT scan) and bioprosthetic valve implantation without contrast medium. All the TAVR procedures were performed using the CoreValve Evolut R/PRO transcatheter aortic valve (Medtronic Inc, Minneapolis, MN, USA). The annulus and the optimal implantation projection were identified on the non-contrast medium CT scans with the aid of calcifications as a reference. The implant projection was confirmed immediately before the valve implantation by placing two pigtail catheters alternately inside each sinus of Valsalva (SOV).
RESULTS: We enrolled 12 patients: mean age 83.42 4.50 years, number of male 5 (41.7%), mean STS 10.33±6.16, mean EuroScore II 13.75±9.07, mean serum creatinine 2.01±0.63 mg/dL, mean eGFR 23.00±5.69 mL/min/1.7m2. All TAVR procedures were successful, leading to a drop in transaortic mean gradient (mean gradient 33.5±14.09 mmHg; postoperative mean gradient 6.08±mmHg). No patient had more than a mild paravalvular leak. Only two patients underwent permanent pacemaker implantation due to advanced atrioventricular block (AV block). Mean change in eGFR 48 hours after the procedure was 1.3 mL/min. None of the patients developed AKI, according to Valve Academic Research Consortium-2 (VARC-2) definition.
CONCLUSIONS: In patients with advanced CKD, a strategy of “zero contrast” TAVR, preceded by accurate CT scan analysis and procedural planning, appears to be safe and feasible permitting to preserve renal function. The avoidance of contrast medium during preprocedural analysis and TAVR implantation could reduce the incidence of AKI and consequently could improve outcomes in this complex patient cohort.


KEY WORDS: Aortic valve; Aortic valve stenosis; Transcatheter aortic valve replacement; Renal insufficiency, chronic; Acute kidney injury

inizio pagina